daVi DigitalMedicine

What daVi DigitalMedicine does

daVi DigitalMedicine srl is a Verona-based digital biotechnology company founded in 2021 that develops patient-facing AI-Native digital health technologies for the treatment and self-management of chronic diseases. The company operates across three product categories: candidate Digital Therapeutics including QPress for arterial hypertension (co-developed with Polifarma spa) and NyxDigital for chronic insomnia (built on CBT-i under the NyxDigital Alliance with the University of Verona, Santer Reply, and Qstep); Care Support ecosystems such as TakeCharge AI for stroke and VisusTrack for age-related macular degeneration (developed within the VIPERMED Net project with Università Cattolica); and Health & Wellness applications including Somnia AI for sleep and Tens AI for hypertension management. All products sit on an AI-Native architecture leveraging Google Cloud's Gemini family of models, Vertex AI Search, Firebase, and Cloud Run, with voice-first interaction via a proprietary Voice-to-Data conversion pipeline, Retrieval-Augmented Generation for scientific grounding against curated clinical guidelines, and an agentic UX design.

The business model blends several revenue streams: subscription-based B2G and B2B pathways targeting national health service reimbursement and insurance companies for digital therapeutics, professional-services revenue from co-development agreements with pharmaceutical companies such as Polifarma spa, and ancillary income from educational publications distributed via Amazon Kindle. Go-to-market combines direct enterprise engagement with healthcare providers, pharma partnerships, and clinical-academic alliances (University of Verona, Università Cattolica, Giuseppe Manni Foundation) alongside event-driven awareness through conferences such as World Sleep Day and European Biotech Week, and a community-led motion through the Fondazione Tendenze Salute Sanità 'Expert Patient' programme. The company is registered as an Italian srl with €10,000 share capital, P.IVA 04796470237.

The organization is at a pre-commercial development stage. Headcount is 1-10 employees, leadership centres on Co-founder & CEO Giuseppe Recchia supported by a small technical team and a broad network of clinical and academic partners, and most products are classified as candidate or in clinical development rather than commercially launched. Geographic footprint is anchored in Italy with an emerging European presence through the DHx France partnership announced in 2025. No funding rounds, revenue figures, or external institutional investors are disclosed in the available data.

Name

daVi DigitalMedicine

Legal name

daVi DigitalMedicine srl

Website

https://davidigitalmedicine.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

daVi DigitalMedicine is a Verona-based AI-first digital biotechnology company developing patient-facing digital therapeutics, care support ecosystems, and health & wellness apps for chronic disease management using voice-first AI-Native architecture on Google Cloud infrastructure.

Ownership category

akta.pro rank

Product category

Digital Therapeutics Software

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

akta.pro secondary industries

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH), Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)

Keywords

• Digital therapeutics
• AI-native digital health
• Patient-facing digital medicine
• Chronic disease management
• Digital care support

Headquarters

HQ city

Verona

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Digital Therapeutics (B2G): Revenue from healthcare system reimbursement (Business to Government) for digital therapeutic products like NyxDigital. Target market includes potential reimbursement by national health services and insurance companies.
2. Digital Therapeutics (B2B): Revenue from insurance companies and employer health plans for digital therapeutic solutions. Business model includes awareness that chronic disease treatment reimbursement is evolving.
3. Co-development Partnerships with Pharma: Joint development partnerships with pharmaceutical companies (e.g., Polifarma spa for QPress digital therapeutic for arterial hypertension) generating revenue through R&D collaboration agreements.
4. Educational Publications: Revenue from publishing educational materials including AI manuals and guides, distributed through platforms like Amazon.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

Core offering

daVi DigitalMedicine develops AI-Native patient-facing digital health technologies including digital therapeutics, care support tools, and health & wellness applications for chronic disease treatment and self-management. Its portfolio spans candidate Digital Therapeutics (QPress for hypertension, NyxDigital for chronic insomnia), Care Support ecosystems (TakeCharge AI for stroke, VisusTrack for macular degeneration), and Health & Wellness apps (Somnia AI for sleep, Tens AI for blood pressure), all built on voice-first AI-Native architecture with proprietary Voice-to-Data processing and RAG-based scientific grounding.

Product overview

daVi DigitalMedicine is an AI-first Digital Medicine Company developing patient-facing digital health technologies across three domains: Digital Therapeutics (DTx) for treatment of chronic diseases, Care Support tools for disease self-management, and Health & Wellness applications. The core product portfolio includes: Somnia AI (AI-Native sleep well-being app), Tens AI (AI-Native blood pressure management app), TakeCharge AI (stroke care support), NyxDigital (candidate DTx for chronic insomnia), QPress (candidate DTx ecosystem for hypertension), and VisusTrack (care support ecosystem for age-related macular degeneration with app, web, and AI bot components). The company also develops AI agents (daViBot, VisusTrackBot, daVi-AI-Bot, HyperBot1) and maintains web platforms (Digital Medicine Portal, daVi-AI-Web). Products are built on AI-Native architecture using voice-first interfaces, Voice-to-Data technology, RAG-based scientific grounding, and agentic UX design. The portfolio follows a platform-plus-specialized-applications model where AI-native core capabilities are adapted for specific therapeutic areas (sleep, blood pressure, stroke, insomnia, eye health, cognitive decline).

Differentiator

Problem solved

Functional benefit

Brands

• daViBot: AI Agent for general digital medicine inquiries.
• VisusTrackBot
• daVi-AI-Bot
• QPress
• NyxDigital
• Somnia AI
• Tens AI
• TakeCharge AI
• HyperBot1
• G3-ARCH-PRO

Quantifiable outcome

• Engagement exceeding 6 hours per study period demonstrated by comparable AI-based DTx (Therabot, NEJM AI 2025) with therapeutic alliance comparable to human therapists

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability13 records

Feature7 records

Partnerships

Twelve partnerships are on record, tiered minor and core.

• DHx FranceminorGTM or Marketing Partner · 1 January 2025Partnership with DHx France (Digital Health Experience) - the distinguished forum for exploring frontiers of digital health innovation in France and Europe. daVi endorses and supports the evolution of digital therapeutics landscape.
• Giacomo CarollocoreStrategic or Co-development Partner · 1 January 2025Strategic collaboration with Giacomo Carollo, psychologist and expert researcher in digital therapies and virtual reality, for CareMind project developing AI-enabled digital technologies for mental health management including anxiety, depression, and cognitive disorders.
• Pharma & Biotech Advisors srlminorGTM or Marketing Partner · 1 January 2025Co-organizer with Pharma & Biotech Advisors srl of Biotech Week 2025 YouTube conference 'BioTecnologIA - Biotech meets AI'.
• Fondazione Tendenze Salute SanitàcoreStrategic or Co-development Partner · 1 January 2023Since 2023, daVi DigitalMedicine has been a participating company of Trends in Health & Healthcare Foundation (Fondazione Tendenze Salute Sanità), Verona - a not for profit foundation devoted to the progress of healthcare and leading player in Digital Medicine. Hosts Expert Patient in... programme.
• VIPERMED Net Enterprise NetworkcoreStrategic or Co-development Partner · 1 January 2023Since 2023, daVi DigitalMedicine has been a member of VIPERMED Net Enterprise Network engaged in the realisation of the VIPERMED project 'Project implemented with financing from the Veneto Development and Cohesion Plan – Special Section'. Coordinates VisusTrack digital ecosystem development.
• Giuseppe Manni Foundation for Research in NeurosciencescoreStrategic or Co-development Partner · 1 January 2022Since 2022, daVi DigitalMedicine has been a partner of Giuseppe Manni Foundation for Research in Neurosciences, Verona for the Digital Tele Medicine project. Foundation supports NyxDigital digital therapeutic candidate for chronic insomnia.
• Polifarma spacoreStrategic or Co-development Partner · 1 January 2021Since 2021, daVi DigitalMedicine has been a partner of Polifarma spa, Rome for the QPress project 'Research & Development of a digital therapeutics ecosystem for arterial hypertension'. Co-development of candidate Digital Therapeutic for hypertension management.
• Medicalstar srlminorStrategic or Co-development Partner · 1 January 2021Since 2021, daVi DigitalMedicine has been a partner of Medicalstar srl, Milan for the Pharmastar Digital Medicine project. Medicalstar is a leading Italian publisher of medical and scientific drug and healthcare information, owner of the online newspaper Pharmastar.
• DigitalRehab srlcoreStrategic or Co-development Partner · 1 January 2021Participating company in DigitalRehab srl, focused on digital motor rehabilitation. AuReha, developed by DigitalRehab, is the first Digital Therapeutic candidate for motor rehabilitation under clinical development in Italy. daVi DigitalMedicine is an innovative startup participated by daVi.
• Laife Reply spacoreTechnology or Integration · 1 January 2021Technology partner for software development of NyxDigital (Discovery phase 2023-2024), VisusTrack (VIPERMED project), and QPress projects. Milan-based enterprise specializing in digital health technology development.
• Department of Engineering for Innovation Medicine, University of VeronacoreStrategic or Co-development Partner · 1 January 2021Public institution partner in NyxDigital Alliance. Manages clinical development pathway including Care Support and Digital Therapeutic confirmatory development. Provides academic research framework.
• Università Cattolica del Sacro Cuore, RomecoreStrategic or Co-development Partner · 1 January 2021Collaboration partner for VIPERMED VisusTrack development, contributing to the digital ecosystem for monitoring and supporting patients with age-related macular degeneration.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Voluntis (Aptar Pharma): Digital therapeutics for oncology and chronic-disease patient support, now part of Aptar Pharma — comparable pharma-partnered DTx model similar to daVi's Polifarma QPress co-development.
• Omada Health: Established digital chronic-disease prevention and management platform (diabetes, hypertension, MSK) — comparable on hypertension (QPress target) and broader chronic-care coaching model, but at much greater scale and with employer/payer reimbursement.
• DarioHealth: Chronic-condition digital therapeutics platform spanning diabetes, hypertension, and behavioral health — directly comparable to daVi's multi-condition DTx portfolio and B2B payer contracting model.

Direct peers

• Kaia Health: Digital therapeutics for chronic conditions (MSK pain, COPD) with AI-coaching app — comparable to daVi's chronic disease DTx model and voice/conversational AI differentiation.
• BehaVR: VR-based digital therapeutics for mental health, chronic pain, and oncology — directly comparable as an AI-/immersive-tech-driven DTx company targeting similar behavioral and chronic-condition indications.
• Big Health: Digital therapeutics company with Sleepio (insomnia CBT-i) and Daylight (anxiety) — directly comparable to daVi's NyxDigital insomnia candidate and the broader insomnia/behavioral-health DTx focus.
• Hinge Health: Largest digital MSK and rehabilitation platform — comparable to daVi's rehabilitation care-support (TakeCharge AI / AuReha) and a benchmark for chronic-condition digital therapy commercialization.
• Akili Interactive: Pioneer in prescription digital therapeutics (EndeavorRx for ADHD) — direct peer in the AI/cognitive DTx category and a benchmark for clinical validation, regulatory, and reimbursement challenges daVi will face.
• Sword Health: Digital rehabilitation/physical therapy platform with AI-guided care — closely comparable to daVi's TakeCharge AI stroke care support and AuReha motor rehabilitation candidate (developed by DigitalRehab srl).
• Click Therapeutics: Prescription digital therapeutics platform with FDA-cleared products across migraine, depression, and schizophrenia — directly comparable to daVi's candidate DTx pipeline and pharma co-development model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/daViDigitalMed1
• YouTubeyoutube.com/@daViDigitalMedicine
• Facebookfacebook.com/daViDigitalMedicine
• LinkedInlinkedin.com/company/davi-digitalmedicine

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about daVi DigitalMedicine